 |
| Modules |  |
| Google |  |
|
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS. | |
| Languages |  |
|
Select Interface Language:
| |
| Who's Online |  |
There are currently, 216 guest(s) and 16 member(s) that are online.
You are Anonymous user. You can register for free by clicking here | |
| Next Step |  |
| Donations |  |
|
To remain unbiased, This is MS does not accept corporate sponsorships. Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you! | |
|  |
 | Rituxan Has Positive Phase II Results |
Biogen, and a new name in the multiple sclerosis world, Genentech, proudly announced today that their Phase II trial of Rituxan against Relapsing-Remitting MS (RRMS) was considered successful. Rituxan was originally approved as a cancer therapy versus non-Hodgkin's Lymphoma. More recently it received approval to treat Rheumatoid Arthritis in combination with methotrexate for patients failing standard therapies.
Rituxan works by depleting B-cells, a type of white blood cell associated with inflammation.
Story continues, please click 'read more'...
|
|
|
Posted by Administrator on Monday, August 28 @ 18:54:07 EDT (5630 reads)
(Read More... | 12710 bytes more | Score: 3.9)
|
|
 | News: New Treatments for Restless Leg Syndrome (RLS) |
PORTLAND, Ore. - Researchers at two Oregon hospitals are studying a common but rarely diagnosed ailment that causes millions of Americans to have a creepy-crawly feeling deep in their leg muscle or involuntarily kick their legs.
The neurological condition, called restless leg, is a nuisance, not life-threatening. But restless leg sufferers are driven to sometimes extreme lengths to move their legs, about the only thing that brings immediate relief.
Researchers at Oregon Health & Science University and Bend Memorial Clinic are participating in national studies to see how effective certain medicines are in treating the condition.
|
|
|
Posted by Administrator on Monday, January 26 @ 13:23:02 EST (2762 reads)
(Read More... | 3649 bytes more | News | Score: 4)
|
|
 | Clinical Trials: Laugh at Funerals? Avanir's NeuroDex intended for Emotional Lability Treatment |
"[Sufferers of neurological disorders] can face daunting physical rehabilitation challenges that may be complicated by uncontrollable outbursts of emotions, such as laughing or crying. This condition, called pseudobulbar affect (PBA) or emotional lability, may affect up to one third of the four million stroke survivors in the U.S. today.
PBA affects a diverse population of patients with neurologic disorders, including those with Alzheimer's, multiple sclerosis, Lou Gehrig's disease or ALS, Parkinson's, and those with neuronal damage following stroke or traumatic brain injury. While the underlying causes of PBA vary from patient to patient, those with the condition experience uncontrolled emotional outbursts and inappropriate responses to various situations. In the simplest terms, PBA can cause a stroke survivor to laugh at a funeral or cry at the circus."
Click "Read More" below for the full story.
|
|
|
Posted by Administrator on Monday, December 29 @ 15:29:58 EST (1733 reads)
(Read More... | 5837 bytes more | Clinical Trials | Score: 5)
|
|
 | Clinical Trials: Millenium begins test on inflammation treatment MLN3897 |
Millennium Pharmaceuticals Inc. in Cambridge has launched Phase I clinical trials for a drug intended to reduce inflammation in conditions ranging from rheumatoid arthritis to multiple sclerosis and psoriasis. The drug, MLN3897, is the first to reach clinical trials stemming from an alliance with Aventis Pharmaceuticals Inc. in Bridgewater, N.J., formed in 2000 to find new therapies for inflammatory diseases.
|
|
|
Posted by Administrator on Monday, December 22 @ 18:04:44 EST (1836 reads)
(Read More... | 3118 bytes more | Clinical Trials | Score: 0)
|
|
 | Clinical Trials: Genzyme Announces Start of Phase 1 Trial of Genz-29155 for Multiple Sclerosis |
Add another drug to the pipeline!
Genzyme Corporation announced today that physicians have treated the first participants in a Phase 1 clinical trial to test the safety of Genz-29155, a small molecule developed by Genzyme for the treatment of multiple sclerosis.
...
Genz-29155, which was discovered through high throughput screening at Genzyme, has shown an ability in vitro to inhibit some, but not all, of the activities of tumor necrosis factor (TNF), a protein active in the regulation of certain immune responses. In vivo, Genz-29155 has shown potential to have an effect not only in models of multiple sclerosis, but of other immune- mediated diseases as well.
|
|
|
Posted by Administrator on Friday, December 12 @ 13:37:33 EST (1743 reads)
(Read More... | 6027 bytes more | Clinical Trials | Score: 5)
|
|
 | Clinical Trials: First Patient Enrolled in new Betaferon Study |
Schering AG, Germany announced today that the first multiple sclerosis (MS) patient has entered the second phase of the BEYOND trial. This compares the efficacy of a new, higher-dose Betaferon® (500 mcg) with Betaferon 250 mcg and glatiramer acetate (Copaxone) in patients with relapsing-remitting MS. Recently, the company announced positive safety and tolerability data from the first phase of the study program examining Betaferon 250 mcg and Betaferon 500 mcg.
|
|
|
Posted by Administrator on Tuesday, December 09 @ 14:02:53 EST (2014 reads)
(Read More... | 4342 bytes more | Clinical Trials | Score: 3)
|
|
|  |
| Login |  |
|
Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name. | |
| Survey |  |
| Big Story of Today |  |
|
There isn't a Biggest Story for Today, yet. | |
| Old Articles |  |
|
There isn't content right now for this block. | |
| Latest Forum Posts |  |
|